Insights Into Marginal Zone Lymphoma

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.